India, June 23 -- Phathom Pharmaceuticals, Inc. (PHAT), which develops treatments for gastrointestinal diseases, on Tuesday announced that it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA (vonoprazan) tablets for Eosinophilic Esophagitis in adults.
Eosinophilic esophagitis (EoE) is a chronic immune condition of the esophagus where white blood cells called eosinophils build up in the lining, causing inflammation, painful swallowing, choking, and food impaction.
VOQUEZNA (vonoprazan) is a potassium-competitive acid blocker (PCAB) approved by the FDA for adults for the treatment of erosive esophagitis (EE) associated with GERD, relief of heartburn associated with non-erosive gastroesophageal reflu...